

Tislelizumab

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

ATC codes

[L01FF09](#)

Medicine type

Biological agent

EML status history

Application rejected in 2021 ([TRS 1035](#)) for [Hodgkin lymphoma](#)

Application rejected in 2021 ([TRS 1035](#)) for [Malignant neoplasms of urinary tract](#)

Application rejected in 2023 ([TRS 1049](#)) for [Other specified malignant neoplasms of bronchus or lung](#)

Application rejected in 2025 ([TRS 1064](#)) for [Squamous cell carcinoma of oesophagus](#)

Wikipedia

[Tislelizumab](#)

DrugBank

[Tislelizumab](#)

Recommendations

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

[Hodgkin lymphoma](#) [Malignant neoplasms of urinary tract](#) [Other specified malignant neoplasms of bronchus or lung](#)
[Squamous cell carcinoma of oesophagus](#)